Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3374849 - SC
LY3374849 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3374849 - SC (Part A) | EXPERIMENTAL | Single subcutaneous (SC) dose of LY3374849 |
| Insulin Degludec - SC (Part A) | EXPERIMENTAL | Single SC dose of insulin degludec |
| LY3374849 - SC (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered SC in up to three of three study periods |
| LY3374849 - IV (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods |
| LY3374849 - IV (Part C) | EXPERIMENTAL | Single IV dose of LY3374849 in one of two study periods |
| Insulin Degludec - IV (Part C) | EXPERIMENTAL | Single IV dose of insulin degludec in one of two study periods |
| Name | Type | Description |
|---|---|---|
| LY3374849 - SC | DRUG | Administered SC |
| Insulin Degludec - SC | DRUG | Administered SC |
| LY3374849 - IV | DRUG | Administered IV |
| Insulin Degludec - IV | DRUG | Administered IV |
Inclusion Criteria: * Healthy male or a female who cannot become pregnant * Have a body mass index (BMI) of at least 18 kilogram per square meter (kg/m²) * Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study * Ha...
LY3374849 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development rather than being an approved medicine.
LY3374849 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in healthy volunteers.
LY3374849 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. Because only early-stage testing in healthy participants has been completed, LY3374849 is investigational and has not been approved by the FDA for any use.
LY3374849 has been evaluated in one completed Phase 1 trial, NCT03726125, titled A Study of LY3374849 in Healthy Participants. The trial enrolled 89 healthy volunteers in Singapore, was randomized, double-blind, and controlled, and included participants aged 21 years and older.
Yes, LY3374849 - SC is an alternative name used for LY3374849. Both names refer to the same investigational small molecule developed by Eli Lilly and Company, so searches using either name point to the same compound and the same Phase 1 program.